Sotigalimab
- Generic Name
- Sotigalimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2305607-45-6
- Unique Ingredient Identifier
- JEA93WJ5DG
- Background
Sotigalimab is under investigation in clinical trial NCT03123783 (CD40 Agonistic Antibody APX005M in Combination With Nivolumab).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Apexigen America, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04337931
- Locations
- 🇵🇱
Centrum Onkologii - Instytutu im. Marii Skłodowskiej - Curie w Warszawie, Warsaw, Poland
🇵🇱Szpital Kliniczny im. Heliodora Święcickiego UM w Poznaniu, Poznan, Poland
🇪🇸Hospital Universitari Vall D'Hebron, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath